2026年生物技术与生命科学26大关键趋势：从AI驱动到全球监管重塑 Translation: 26 Key Trends in Biotechnology and Life Sciences for 2026: From AI-Driven to Global Regulatory Reshaping

Introduction

In 2026, the field of biotechnology and life sciences enters a new stage dominated by execution rather than expectations. Faster R&D cycles, smarter clinical trial designs, and expanding global markets are reshaping how therapies are discovered, developed, and delivered. Meanwhile, regulatory frameworks are tightening, capital is becoming more selective, and strategic M&A is redefining competitive advantages. From AI-driven molecular discovery to clinical breakthroughs in gene editing, from EU pharmaceutical reform to Sino-US geopolitical rivalry, this article integrates 26 trends across four dimensions—science, market, regulation, and business—to provide key references for industry leaders, investors, and innovators.

Industry Context

After experiencing rapid growth from 2020 to 2025, the biotechnology industry is entering a period of rational adjustment. The financing boom triggered by the COVID-19 pandemic is gradually receding, and the capital market is no longer tolerant of projects lacking clinical differentiation. Instead, technology platforms that can significantly shorten R&D timelines and improve success rates, as well as innovative therapies targeting unmet medical needs, continue to attract substantial funding. At the same time, global regulators are adjusting rules in parallel: the EU has introduced the Pharmaceutical Package and the AI Act, the US FDA has introduced a "reasonable mechanism" to accelerate approval pathways, and China's NMPA accepts multi-regional clinical trial data. These changes mean that companies must find new strategic footholds within a complex international regulatory environment.

Key Developments

AI and Machine Learning: From Tools to Scientific Infrastructure

AI/ML is no longer an auxiliary tool in biopharmaceutical R&D but rather core infrastructure. Eli Lilly and NVIDIA have partnered to build supercomputers for molecular simulation, and nearly half of industry executives rank digital transformation and AI as top strategic drivers. AI platforms are accelerating drug discovery processes, including target identification, molecule design, clinical trial optimization, and real-time data analysis. Venture capital is flowing heavily into AI-driven diagnostics and remote health tools. Sapio Sciences notes that cloud computing and analytics are "reshaping drug discovery, personalized medicine, and healthcare delivery."

The Explosion of Synthetic Biology and Bioengineering

Customized biological systems—from engineered cells to novel biomolecules—are becoming a disruptive trend. Researchers are leveraging synthetic biology to develop new gene and RNA therapies, protein materials, and biofuels with unprecedented efficiency. For example, companies are engineering microorganisms to produce complex drugs, and advancing programmable cell therapies and vaccines. The convergence of biology and engineering promises to address unmet needs in medicine, agriculture, and sustainability.

Gene Editing and Precision Genomics Rapidly Advancing

Gene Editing and Precision Genomics Advance Rapidly

CRISPR-Cas9 and novel base editing tools are moving from the lab to the clinic. In 2023, Beam Therapeutics treated its first patient with its CRISPR-derived base editing therapy, signaling broader adoption. The future will see more in vivo gene editing trials, refined delivery systems, and whole-genome editing platforms for somatic and germline applications. These technologies lay the foundation for personalized medicine and the treatment of rare genetic diseases.

Advanced Therapeutic Modalities Reshape Pipelines

Cell and gene therapies (CGTs) continue to expand, including CAR-T, TCR, and gene replacement therapies. By mid-2025, the FDA had approved 46 cell/gene therapy products and introduced a new "reasonable mechanism" pathway to accelerate highly personalized treatments. In oncology, in vivo CAR-T (injectable genetic programs) and bispecific antibodies are gaining traction. Next-generation biologics (bispecific antibodies, ADCs, radiopharmaceuticals) are expected to provide more effective and durable cancer treatments.

Microbiome and Immunotherapy Enter the Mainstream

After years of R&D, microbiome ecological drugs are entering the market. Australia's TGA approved BiomeBank's Biomictra (the first donor-derived microbiome therapy for recurrent Clostridium difficile infection); in Europe, MaaT Pharma reported positive Phase 3 clinical results and has submitted a marketing application for its lead microbiome drug. As more pipelines advance, microbiome drugs are becoming a true medical frontier.

Digital Health and Diagnostics Continue to Evolve

Wearables, digital biomarkers, and telemedicine are being integrated into clinical trials and care pathways. Real-time analytics and AI improve patient monitoring; for example, Cleveland Clinic uses AI tools to scan unstructured medical notes to recruit subjects. Venture capital is flowing into digital health platforms, including remote monitoring, apps, and AI-assisted telehealth. AI-driven imaging and predictive analytics are transforming diagnostics, enabling abnormalities to be identified faster than humans and facilitating early disease detection.

Automation and Smart Manufacturing Mature

Biopharmaceutical manufacturers are adopting robotics, single-use bioreactors, continuous processing, and IoT sensors to improve yield and flexibility. An industry survey shows that 85% of life sciences companies have increased supply chain and digital manufacturing investments (totaling $1.3 trillion). Automation has become central to modern manufacturing, helping reduce errors, scale up cell therapy production, and drive local production of critical materials.

Early Potential of Quantum Computing

Although quantum computing is still in its infancy, it has the potential to be a game changer. Early platforms can simulate complex molecular interactions that classical computers cannot handle. Experts predict that as hardware matures, quantum systems will dramatically accelerate drug discovery by simulating chemical processes at an unprecedented scale.

Emerging Markets and Fields: From Agriculture to Global Expansion Biotechnology is diversifying into new markets and applications. Personalized medicine and preventive medicine are expanding beyond rare diseases. Advances in genomics and biomarkers are making treatments increasingly precise. In 2025, CGT investment reached $15.2 billion, up 30% from 2023. Agricultural and environmental biotechnology are also on the rise, with gene-edited crops, microbial soil improvement, precision agriculture, and renewable bioenergy accelerating to address food security and climate resilience needs. Global expansion is particularly notable: China concluded over 140 licensing and investment deals in 2025, and despite trade tensions, deal volume remained near record levels. China's NMPA has begun accepting multi-regional clinical trial data, facilitating simultaneous submissions in China and the U.S. The Asia-Pacific region is fostering innovation hubs, such as Japan focusing on gene therapy and India developing biosimilars.

Market Implications

These technological trends are reshaping the market landscape. AI and automation have lowered R&D costs, enabling more small and mid-sized biotech companies to participate in innovation. Synthetic biology and advanced therapies have opened up new therapeutic areas, but they also require higher manufacturing capabilities and capital investment. Global regulation is becoming stricter, especially the EU pharmaceutical package and AI Act, which will affect data use and AI applications; companies need to ensure compliance in advance. At the same time, drug pricing pressures persist: China's volume-based procurement is driving down prices, U.S. Medicare reform is contentious, and value-based contracts and patient access programs are on the rise. Capital is increasingly favoring First-in-class assets with clear differentiation pathways over Me-too products. M&A activity is focused on acquiring innovation platforms and pipelines, particularly in gene editing, AI drug discovery, and microbiome fields.

Challenges And Risks

Despite the optimistic outlook, the industry still faces significant challenges. The safety and ethical issues of gene editing have not been fully resolved, especially the controversy over germline editing. The interpretability of AI models and data bias need careful handling. The mechanisms of action of microbiome therapies are complex, and the regulatory pathways are not yet clear. Synthetic biology may introduce biosecurity risks and requires strong governance. Moreover, geopolitical tensions are fragmenting supply chains: the Biosecure Act restricts investment in specific Chinese entities, while the EU's Critical Medicines Act requires supply chain mapping and localized production, which will increase compliance costs. ESG reporting pressures are also rising, and companies need to balance sustainability goals with R&D investment. Finally, expectations for quantum computing and AI may exceed reality, and investors should be wary of bubble risks.

Future OutlookLooking ahead over the next 3–5 years, the biotechnology and life sciences industry will present the following trends: AI and quantum computing will become deeply integrated, ushering drug discovery into the ultra-high-throughput era. In the field of gene editing, in vivo editing and base editing will become more common, and precision medicine will become mainstream. Cell therapy will gradually shift from autologous to universal approaches, with manufacturing costs declining. Microbiome-based drugs are expected to receive approval for multiple indications, becoming a new option for chronic disease management. Digital health and wearable devices will be seamlessly integrated into clinical workflows. On the regulatory front, the trend toward global harmonization will strengthen; unified ICH guidelines and mutual recognition of multi-regional trials will accelerate simultaneous global drug launches. However, pricing and market access remain major bottlenecks, and value-based payment models will gradually replace simple price negotiations. Capital will pay greater attention to companies with genuine clinical value and technological barriers, M&A activity is expected to remain active, and large pharmaceutical companies will continue to acquire innovative technology platforms. Sustainability and ESG will shift from optional to mandatory, affecting corporate financing and market access.